Using a Kras driven mouse model of lung cancer, Soucek et al. targeted MYC using a dominant negative MYC dimerization domain mutant disrupting MYC binding to canonical Myc E-box response element ‘CACGTG’, thereby inhibiting MYC transactivation activity41. The gene discussed is KRAS; the disease is lung cancer.